Beactica Therapeutics

CompanySweden

Beactica Therapeutics develops one asset, preclinical (BEA-28 in biomarker-selected cancers). Mostly small molecule acting on TEAD1, TEAD2 and TEAD3; based in Sweden.

1
Asset
Furthest stage: Preclinical; 0
Trials: 0
Signals

Pipeline

1

BEA-28
Targeted protein degradation of TEAD transcription factors
Preclinical, Small molecule, TEAD1, TEAD2, biomarker-selected cancers, cancer

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms3
Similar companies6